QQQ   423.48 (-0.90%)
AAPL   181.41 (-0.08%)
MSFT   399.17 (-0.90%)
META   467.57 (-0.78%)
GOOGL   142.18 (+0.75%)
AMZN   167.58 (+0.30%)
TSLA   192.30 (-0.75%)
NVDA   671.04 (-3.38%)
NIO   6.02 (+1.01%)
AMD   163.32 (-1.43%)
BABA   75.63 (+3.40%)
T   16.97 (+0.35%)
F   12.08 (-1.39%)
MU   80.59 (-0.15%)
CGC   3.39 (-4.24%)
GE   148.22 (-0.27%)
DIS   107.71 (-1.58%)
AMC   4.57 (-1.93%)
PFE   27.47 (-0.43%)
PYPL   57.61 (-1.74%)
XOM   104.37 (+1.58%)
QQQ   423.48 (-0.90%)
AAPL   181.41 (-0.08%)
MSFT   399.17 (-0.90%)
META   467.57 (-0.78%)
GOOGL   142.18 (+0.75%)
AMZN   167.58 (+0.30%)
TSLA   192.30 (-0.75%)
NVDA   671.04 (-3.38%)
NIO   6.02 (+1.01%)
AMD   163.32 (-1.43%)
BABA   75.63 (+3.40%)
T   16.97 (+0.35%)
F   12.08 (-1.39%)
MU   80.59 (-0.15%)
CGC   3.39 (-4.24%)
GE   148.22 (-0.27%)
DIS   107.71 (-1.58%)
AMC   4.57 (-1.93%)
PFE   27.47 (-0.43%)
PYPL   57.61 (-1.74%)
XOM   104.37 (+1.58%)
QQQ   423.48 (-0.90%)
AAPL   181.41 (-0.08%)
MSFT   399.17 (-0.90%)
META   467.57 (-0.78%)
GOOGL   142.18 (+0.75%)
AMZN   167.58 (+0.30%)
TSLA   192.30 (-0.75%)
NVDA   671.04 (-3.38%)
NIO   6.02 (+1.01%)
AMD   163.32 (-1.43%)
BABA   75.63 (+3.40%)
T   16.97 (+0.35%)
F   12.08 (-1.39%)
MU   80.59 (-0.15%)
CGC   3.39 (-4.24%)
GE   148.22 (-0.27%)
DIS   107.71 (-1.58%)
AMC   4.57 (-1.93%)
PFE   27.47 (-0.43%)
PYPL   57.61 (-1.74%)
XOM   104.37 (+1.58%)
QQQ   423.48 (-0.90%)
AAPL   181.41 (-0.08%)
MSFT   399.17 (-0.90%)
META   467.57 (-0.78%)
GOOGL   142.18 (+0.75%)
AMZN   167.58 (+0.30%)
TSLA   192.30 (-0.75%)
NVDA   671.04 (-3.38%)
NIO   6.02 (+1.01%)
AMD   163.32 (-1.43%)
BABA   75.63 (+3.40%)
T   16.97 (+0.35%)
F   12.08 (-1.39%)
MU   80.59 (-0.15%)
CGC   3.39 (-4.24%)
GE   148.22 (-0.27%)
DIS   107.71 (-1.58%)
AMC   4.57 (-1.93%)
PFE   27.47 (-0.43%)
PYPL   57.61 (-1.74%)
XOM   104.37 (+1.58%)
NASDAQ:MDXG

MiMedx Group (MDXG) Stock Price, News & Analysis

$8.01
-0.03 (-0.37%)
(As of 01:10 PM ET)
Today's Range
$7.95
$8.10
50-Day Range
$7.68
$9.14
52-Week Range
$3.08
$9.27
Volume
183,398 shs
Average Volume
614,056 shs
Market Capitalization
$932.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.67

MiMedx Group MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
45.7% Upside
$11.67 Price Target
Short Interest
Bearish
5.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.57mentions of MiMedx Group in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$35,800 Bought Last Quarter
Proj. Earnings Growth
277.78%
From $0.09 to $0.34 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.03 out of 5 stars

Medical Sector

375th out of 932 stocks

Surgical & Medical Instruments Industry

47th out of 95 stocks


MDXG stock logo

About MiMedx Group Stock (NASDAQ:MDXG)

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.

MDXG Stock Price History

MDXG Stock News Headlines

MiMedx Group (MDXG) Set to Announce Earnings on Wednesday
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
MDXG Mar 2024 7.500 call
MDXG Jun 2024 15.000 call
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
MiMedx Group: Restructuring Changes Are Paying Off
MDXG: Axiofill Update & Series B Conversion
MiMedx Receives FDA Warning Letter On Axiofill Production
Stocks to Watch: MiMedx Group, Nokia
MiMedx Group Shares Fall 6.5% on FDA Warning Letter
See More Headlines
Receive MDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
2/21/2024
Next Earnings (Confirmed)
2/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:MDXG
Employees
867
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.67
High Stock Price Target
$12.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+45.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-30,200,000.00
Pretax Margin
1.60%

Debt

Sales & Book Value

Annual Sales
$267.84 million
Book Value
($0.16) per share

Miscellaneous

Free Float
93,218,000
Market Cap
$935.70 million
Optionable
Optionable
Beta
1.36
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. William F. Hulse IV (Age 50)
    General Counsel & Chief Administrative Officer
    Comp: $677.36k
  • Dr. Robert Benjamin Stein M.D. (Age 73)
    Ph.D., President of Regenerative Medicine & Biologics Innovation
    Comp: $639.28k
  • Mr. Joseph H. Capper (Age 60)
    CEO & Director
  • Mr. Douglas C. Rice CPA (Age 58)
    Chief Financial Officer
  • Mr. Scott M. Turner (Age 58)
    Senior Vice President of Operations & Procurement
    Comp: $493.98k
  • Mr. Matthew M. Notarianni
    Head of Investor Relations
  • Mr. Mark P. Graves (Age 58)
    Senior VP & Chief Compliance Officer
  • Hilary Dixon
    Vice President of Investor Relations & Corporate Strategic Communications
  • Ms. Kate Surdez
    Chief Human Resources Officer
  • Dr. David H. Mason Jr. (Age 77)
    Chief Medical Officer














MDXG Stock Analysis - Frequently Asked Questions

Should I buy or sell MiMedx Group stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDXG shares.
View MDXG analyst ratings
or view top-rated stocks.

What is MiMedx Group's stock price target for 2024?

3 brokers have issued 12 month target prices for MiMedx Group's shares. Their MDXG share price targets range from $11.00 to $12.00. On average, they anticipate the company's stock price to reach $11.67 in the next year. This suggests a possible upside of 45.7% from the stock's current price.
View analysts price targets for MDXG
or view top-rated stocks among Wall Street analysts.

How have MDXG shares performed in 2024?

MiMedx Group's stock was trading at $8.77 at the beginning of the year. Since then, MDXG shares have decreased by 8.7% and is now trading at $8.01.
View the best growth stocks for 2024 here
.

When is MiMedx Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our MDXG earnings forecast
.

How can I listen to MiMedx Group's earnings call?

MiMedx Group will be holding an earnings conference call on Wednesday, February 28th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were MiMedx Group's earnings last quarter?

MiMedx Group, Inc. (NASDAQ:MDXG) posted its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.04. The business earned $63.07 million during the quarter, compared to the consensus estimate of $60.26 million. During the same quarter in the previous year, the company earned ($0.48) EPS.

What ETF holds MiMedx Group's stock ?

Invesco Nasdaq Future Gen 200 ETF holds 5,917 shares of MDXG stock, representing 0.64% of its portfolio.

Who are MiMedx Group's major shareholders?

MiMedx Group's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.64%), Cannell Capital LLC (2.13%), Richmond Brothers Inc. (1.21%), Charles Schwab Investment Management Inc. (0.97%), Royal Bank of Canada (0.93%) and Northern Trust Corp (0.93%). Insiders that own company stock include Mark Graves, Peter M Carlson, Rice Doug, Robert Benjamin Stein, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan.
View institutional ownership trends
.

How do I buy shares of MiMedx Group?

Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MDXG) was last updated on 2/21/2024 by MarketBeat.com Staff